Fig. 8
Effect of rimonabant on the expression of inflammation markers. The bar graph shows the expression levels of myosin heavy chain (MyHC) and neonatal-myosin heavy chain (neo-MyHC) (a and c) and/or transforming growth factor β 1 (TGF-β1), tumor necrosis factor α (TNFα), interleukin receptor 6 (IL6R), and inducible nitric oxide synthase (iNOS) (b and d) in the indicated skeletal muscles isolated from control (dark yellow), mdx mice + vehicle (DMSO, red columns) and mdx mice + rimonabant (0.5 mg Kg−1, green columns). Each bar is the mean ± SEM of six separate determinations. e, f Plasma levels of IL6 and TNFα quantified by ELISA in control (n = 4) and mdx mice treated with vehicle (DMSO; n = 4) or rimonabant 0.5 (n = 4) mg Kg−1. *P ≤ 0.05 vs. vehicle group, determined by Student’s t test
